CareDx Inc. has announced pivotal clinical validation results for AlloHeme™, a next-generation sequencing $(NGS)$-based and artificial intelligence $(AI)$-powered monitoring test designed to predict relapse in patients with acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) following allogeneic hematopoietic cell transplant (HCT). The data, generated as part of the ACROBAT study (NCT04635384), were presented at the 2026 Tandem Meetings. AlloHeme is a non-invasive, ultra-sensitive blood-based surveillance solution that identified cancer relapse earlier than standard monitoring methods. CareDx plans a sequenced U.S. launch starting with CLIA readiness in 2026, commercial introduction in 2027, and anticipated payer coverage in 2028.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CareDx Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260212430487) on February 12, 2026, and is solely responsible for the information contained therein.